The predictive and prognostic biomarkers for ICIs have been developed by estimating the expression levels of immune checkpoint genes including PD-1, PD-L1 and CTLA4 as well as mutational burden in cancer samples, but the heterogeneity of tumor microenvironment around tumor cells was not considered7. This evidence concerns the gene CTLA4 and neoplasm.